# Study of Long-Term Efficacy and Safety of LIB003 in CVD or High Risk for CVD Patients Needing Further LDL-C Reduction

Study · id `cardio:ct-nct04806893` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04806893](<https://clinicaltrials.gov/study/NCT04806893>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04806893

Browse, organ or system: Heart; Metabolism  
Browse, condition area: Risk and prevention; Coronary and vascular disease; Diabetes and metabolic disease; Acute care and long-term living  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 900 participants.

## Technical summary

Registry record NCT04806893. Randomized; quadruple masking; primary purpose treatment. Start 2021-04-22 (actual); primary completion 2023-11-15 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 900 participants (planned count; ClinicalTrials.gov record NCT04806893, source copy `cardio:ctgov-nct04806893-2023-12-11`, retrieved 2026-10-26)
- Started: 2021-04-22 (actual) (ClinicalTrials.gov record NCT04806893, source copy `cardio:ctgov-nct04806893-2023-12-11`, retrieved 2026-10-26)
- Primary completion: 2023-11-15 (actual) (ClinicalTrials.gov record NCT04806893, source copy `cardio:ctgov-nct04806893-2023-12-11`, retrieved 2026-10-26)
- Completion: 2024-02-28 (anticipated) (ClinicalTrials.gov record NCT04806893, source copy `cardio:ctgov-nct04806893-2023-12-11`, retrieved 2026-10-26)
- Countries: United States; India; Israel (ClinicalTrials.gov record NCT04806893, source copy `cardio:ctgov-nct04806893-2023-12-11`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04806893-2023-12-11`, retrieved 2026-10-26)

## The registry's words

- Brief title: Study of Long-Term Efficacy and Safety of LIB003 in CVD or High Risk for CVD Patients Needing Further LDL-C Reduction
- Acronym: LIBerate-HR
- Condition: Cardiovascular Risk Factor
- Condition: Cardiovascular Diseases
- Condition: Cardiovascular Stroke
- Condition: Hypercholesterolemia
- Intervention (Drug): lerodalcibep
- Intervention (Other): Placebo
- Lead sponsor: LIB Therapeutics LLC
- Lead sponsor class: INDUSTRY
- Collaborator: Medpace, Inc.
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: High cholesterol (hypercholesterolemia) (`cardio:hypercholesterolemia`)
- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry lists this organization as the lead sponsor: LIB Therapeutics LLC (`cardio:org-lib-therapeutics-llc`)
- Registry lists this organization as a collaborator: Medpace, Inc. (`cardio:org-medpace-inc`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Efficacy and Safety of Lerodalcibep in Patients With or at High Risk of Cardiovascular Disease: A Randomized Clinical Trial (`cardio:pubmed-38958989`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: f27cd7839cdd39da3b09b47d0ad64e51a2d216283f694ae9fb9d686a79dbfa3d
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
